# United States Drug Patent 10,610,502: Claim Scope, Baclofen Formulation Protection, and Generic Entry Risk

US Patent No. 10,610,502 is a narrow method-of-treatment patent directed to baclofen aqueous oral solutions that satisfy two linked conditions: control of a specified degradation impurity and refrigerated storage before administration. Claim 1 requires every listed formulation, testing, storage, and treatment limitation. Claim 2 narrows the impurity threshold to 0.2%.

The patent does not broadly claim all baclofen oral solutions. Its commercial significance depends on whether a marketed or proposed generic product uses a citrate-buffered aqueous solution, reaches the claimed impurity condition, undergoes the claimed determination step, and is stored at approximately 2 to 8°C before administration.

What does US Patent 10,610,502 claim?

The independent claim covers a method comprising:

Treating muscle relaxation or spasticity.
Administering an effective amount of an aqueous oral solution.
Using baclofen as an active ingredient.
Using a buffer containing citric acid, a citrate salt, or both.
Optionally including one or more preservatives.
Determining, before administration, that a specified impurity is below a threshold.
Storing the solution after that determination and before administration at approximately 2 to 8°C.

Claim 2 specifies that the threshold is 0.2%.[1]

The claimed impurity is identified as:

“4-(3-carboxymethyl)-3-hydroxy-2,5-dioxopyrrolidin-1-yl)-3-(4-chlorophenyl)butanoic acid.”

The claim therefore combines product characteristics with process and use limitations. It is not simply a claim to baclofen, a citrate buffer, or refrigerated storage in isolation.

Claim limitation matrix

Limitation	Required by claim 1?	Scope implication
Method of relaxing muscles or treating spasticity	Yes	A composition-only sale theory is insufficient without a treatment-use connection
Subject in need thereof	Yes	Requires treatment of an appropriate patient
Effective amount	Yes	Dose must have the claimed therapeutic purpose
Aqueous oral solution	Yes	Excludes tablets, capsules, injectable products, and nonaqueous liquids
Baclofen	Yes	Does not cover unrelated muscle relaxants
Citrate buffer	Yes	Requires citric acid, citrate salt, or a combination
Preservative	No	Preservatives are optional
Specified impurity below threshold	Yes	Analytical impurity control is central to the claim
Determination before administration	Yes	The claim recites a testing or determination event
Storage after determination	Yes	Sequence matters
Storage at approximately 2 to 8°C	Yes	Room-temperature-only storage would generally fall outside the literal storage limitation
Administration to subject	Yes	Required act for method infringement
0.2% threshold	Only claim 2	Claim 1 may cover a different threshold, depending on construction

How broad is the baclofen oral-solution patent?

The practical scope is narrower than the claim’s long wording suggests.

The patent reaches a specific combination of a baclofen liquid, citrate buffering, impurity testing, and refrigerated storage. It does not expressly require a particular baclofen concentration, preservative, container, flavoring agent, pH, dose volume, or brand name. Those omissions give the claim breadth within the defined formulation category.

The claim also does not require preservatives. A generic manufacturer cannot avoid claim 1 merely by omitting a preservative if all other limitations are met.

The principal design-around routes are:

Use of a non-citrate buffer, if technically and regulatorily acceptable.
Use of a nonaqueous dosage form.
Use of a solid dosage form.
Avoidance of the claimed refrigerated storage sequence.
Use of a formulation that does not contain the specified impurity below the claimed threshold in the relevant analytical sense.
Use of a different administration method or therapeutic indication, subject to induced-infringement and label theories.

A design-around based only on changing excipients may fail if the replacement formulation remains an aqueous baclofen solution with citrate buffering and follows the same testing and refrigeration protocol.

What formulation characteristics are protected?

Aqueous oral solution

The claim is limited to an aqueous oral solution. This excludes standard baclofen tablets and other solid oral products from literal coverage by claim 1.

“Aqueous” generally indicates that water is the principal liquid vehicle. The claim does not state a minimum water percentage. Construction could become important for solutions containing substantial amounts of cosolvents, alcohols, polyols, or other nonaqueous ingredients.

Citrate buffer

The buffer must comprise citric acid, a salt of citric acid, or any combination of those components. The wording may cover:

Citric acid alone when functioning as a buffer component.
Sodium citrate.
Potassium citrate.
Other pharmaceutically acceptable citrate salts.
Citric acid combined with a citrate salt.

A formulation using phosphate, acetate, lactate, tartrate, or another buffer without citrate would present a stronger noninfringement position, assuming no equivalent is found.

Baclofen

The claim does not distinguish between baclofen concentrations, enantiomeric forms, or specific commercial strengths. It requires baclofen in the administered aqueous oral solution.

The absence of a stated concentration is important. A low-strength and high-strength citrate-buffered solution may both satisfy this limitation if the remaining limitations are met.

Preservatives

Preservatives are expressly optional. Claim 1 therefore does not require benzyl alcohol, methylparaben, propylparaben, or any other particular preservative.

How does the impurity limitation affect infringement?

The impurity limitation is the patent’s principal technical restriction. The product must contain less than a specified threshold of the identified degradation product, and the amount must be determined before administration.

Claim 2 fixes the threshold at 0.2%. The claim text does not specify whether 0.2% is measured:

By weight relative to the total solution.
Relative to baclofen.
Relative to a stated label claim.
On an anhydrous basis.
As an area percentage in a chromatographic assay.
By another validated analytical method.

That ambiguity may affect both infringement and validity analysis. In pharmaceutical patents, impurity percentages are normally interpreted in the context of the specification, analytical method, reference standard, and reporting basis. The patent’s written description and prosecution history would control the likely construction.[1]

The phrase “determined to be below a threshold level” creates a separate issue. A product may objectively contain an impurity below 0.2% without anyone performing the claimed determination. Literal infringement may require proof of both the quantitative condition and the claimed determination step.

A patentee could argue that routine quality-control testing satisfies the determination limitation. A generic applicant could argue that testing during manufacturing is not the same as determining the impurity level “prior to administration,” particularly if the claim requires a patient-specific or dispensing-stage determination.

What is the difference between claim 1 and claim 2?

Claim 1 is an independent method claim with an unspecified threshold. Claim 2 depends on claim 1 and limits the threshold to 0.2%.

Issue	Claim 1	Claim 2
Claim type	Independent method claim	Dependent method claim
Impurity threshold	Not numerically specified in the claim text	0.2%
Potential breadth	Broader threshold limitation, but more construction-dependent	Narrower numerical limitation
Proof required	Show the applicable threshold and impurity result	Show impurity below 0.2%
Design-around value	Greater flexibility may exist around the threshold	More direct if product is above 0.2%

Claim 2 is easier to analyze analytically but may be easier to design around if a competing product can maintain the impurity at or above the claimed level without compromising safety, stability, or FDA approval.

What patent expiration date applies to US Patent 10,610,502?

The claim text supplied does not establish the patent’s earliest effective nonprovisional filing date, patent term adjustment, terminal disclaimer, patent term extension, or terminal disclaimer relationship. Those facts determine the enforceable expiration date.

Under US law, utility patents generally expire 20 years from the earliest effective US nonprovisional filing date, subject to patent term adjustment, patent term extension, terminal disclaimers, and other statutory provisions.[2] The grant date alone does not determine expiration.

For commercial diligence, the controlling record should be the USPTO Patent Center file history and the FDA Orange Book patent listing, if the patent is listed for an approved baclofen product. The Orange Book reports listed patent information and associated use codes but does not replace a full USPTO term calculation.[3]

What is the Orange Book status of US Patent 10,610,502?

The claim text does not establish whether US Patent 10,610,502 is listed in the Orange Book, which NDA owns the listing, or whether the listing covers an active ingredient, formulation, or method of use.

If listed for an approved baclofen oral solution, the patent could support a Paragraph IV certification dispute against an ANDA applicant. A method-of-use listing would be particularly relevant because claim 1 is drafted as a treatment method rather than as a composition claim.

The commercial effect depends on:

The NDA associated with the patent.
The listed use code.
Whether the generic label includes the patented indication.
Whether the applicant uses a section viii statement to carve out the patented use.
Whether the patent remains unexpired.
Whether the patent owner files a timely infringement action.

FDA listing and litigation consequences arise under the Hatch-Waxman framework, including the statutory 30-month stay triggered by a timely infringement action after a Paragraph IV notice.[4]

What Paragraph IV challenge risks exist?

A Paragraph IV challenger could attack the patent through invalidity, noninfringement, or both.

Likely noninfringement positions

A generic applicant may argue that its product:

Uses a non-citrate buffer.
Is not stored at 2 to 8°C.
Is stored before, rather than after, the relevant determination.
Does not perform the claimed determination before administration.
Does not contain the specified impurity below 0.2%.
Uses a label that omits treatment of spasticity or muscle relaxation.
Is dispensed in a manner that does not satisfy the claimed storage sequence.

The strongest position will depend on the approved label, manufacturing controls, pharmacy instructions, and actual product handling.

Likely invalidity positions

Potential validity attacks include:

Anticipation based on prior baclofen oral solutions with citrate buffers and refrigerated storage.
Obviousness based on known baclofen degradation, impurity monitoring, refrigerated storage, and conventional citrate buffering.
Indefiniteness concerning “below a threshold level,” “about 2 to about 8°C,” and the measurement basis for 0.2%.
Written-description or enablement challenges if the specification does not adequately support the claimed impurity-control and storage sequence.

The strongest patentability issue is likely obviousness if prior art taught that baclofen solutions generate the identified degradation product and that refrigeration limits its formation. The patentee would likely rely on an unexpected stability or impurity-control result tied to the claimed sequence.

How strong is the patent estate?

Based only on the supplied claims, US Patent 10,610,502 has moderate claim breadth but potentially meaningful blocking value.

Its strengths are:

It covers a commercially relevant liquid dosage form.
It does not require a specific preservative.
It does not state a narrow baclofen concentration.
It combines formulation and manufacturing-control limitations that may be present in regulated commercial processes.
Claim 1 may cover thresholds broader than the 0.2% value in claim 2.

Its weaknesses are:

It is a method claim, not a broad composition claim.
It requires proof of a pre-administration determination.
It requires a specific refrigeration range and sequence.
It may be vulnerable to analytical-method and claim-construction disputes.
Solid baclofen products are outside its literal formulation scope.
A non-citrate liquid formulation may avoid the principal buffer limitation.

A broader patent estate would normally include separate composition, stability, impurity, container, dosing, manufacturing, and method-of-use claims. No such related patents, continuation patents, assignees, licenses, settlements, or litigation matters are established by the claim text supplied.

What generic launch scenarios exist?

Scenario 1: Same citrate-buffered formulation

A generic using the same buffer class and refrigerated handling faces the highest risk. The applicant would likely need a Paragraph IV strategy, a noninfringement position based on the determination or storage limitations, or a settlement.

Scenario 2: Citrate-free aqueous solution

A citrate-free formulation could avoid literal infringement of the buffer limitation. Regulatory comparability, palatability, pH control, stability, and impurity formation would determine whether this route is commercially viable.

Scenario 3: Room-temperature product

A product stored outside the claimed range could avoid literal infringement, but only if the label, manufacturing process, and actual handling do not satisfy the claimed refrigeration limitation.

Scenario 4: Solid oral product

Tablets and capsules are outside the express aqueous oral-solution limitation. They may compete directly with a liquid product but would not practice the claimed dosage form.

What litigation and licensing issues should investors assess?

No litigation, settlement agreement, license, or patent assignment is identified in the supplied claim text. Those issues require review of the USPTO assignment records, FDA Orange Book, district-court dockets, and Paragraph IV notices.

The highest-value diligence questions are:

Whether the patent is listed against an approved baclofen oral solution.
Whether a use code covers the full indication in claim 1.
Whether related continuation patents extend protection beyond this patent.
Whether the patent owner has settled prior ANDA challenges.
Whether a license permits a generic launch before patent expiration.
Whether the patent has a terminal disclaimer or related-family expiration constraint.
Whether the impurity is measured in the finished product, stability samples, or manufacturing intermediates.

Key Takeaways

US Patent 10,610,502 is a method patent covering treatment with a citrate-buffered aqueous baclofen oral solution.
The claim requires impurity determination before administration and refrigerated storage afterward at approximately 2 to 8°C.
Claim 2 specifies a 0.2% impurity threshold.
The patent does not broadly cover all baclofen products, tablets, capsules, or every oral liquid.
Preservatives are optional and do not provide a reliable design-around.
The main generic defenses are non-citrate buffering, different storage conditions, absence of the claimed determination step, and impurity levels outside the claim.
Orange Book listing, patent expiration, litigation, licenses, settlements, and related patents are not established by the claim text alone.
Commercial risk is highest for a generic that copies the citrate-buffered liquid formulation and its refrigerated quality-control process.

FAQs

Does US Patent 10,610,502 cover baclofen tablets?

No. The asserted claim requires an aqueous oral solution. Baclofen tablets and capsules do not satisfy that express dosage-form limitation.

Can a generic avoid the patent by removing preservatives?

Usually not on that basis alone. Claim 1 makes preservatives optional, so a preservative-free citrate-buffered aqueous solution could still meet the claim.

Does a 0.2% impurity level automatically create infringement?

No. Claim 2 requires the impurity to be below 0.2% and also depends on every limitation of claim 1, including the determination and storage sequence.

Can a generic use a phosphate buffer instead of citrate?

A phosphate-buffered product would have a credible literal noninfringement position because the claim requires citric acid, a citrate salt, or both. Equivalence and prosecution-history issues could still affect the analysis.

Is refrigerated storage alone enough to practice the patent?

No. Refrigeration is only one limitation. The product must also be an aqueous oral baclofen solution with the claimed citrate buffer, satisfy the impurity condition, undergo the required determination, and be administered for the claimed treatment.

References

United States Patent No. 10,610,502, claims 1-2. U.S. Patent and Trademark Office.
United States Code, 35 U.S.C. § 154. Patent term and patent grant provisions.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
United States Code, 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Metacel Pharms Llc	OZOBAX	baclofen	SOLUTION;ORAL	208193-001	Sep 18, 2019		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				TREATMENT OF SPASTICITY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 10,610,502

Which drugs does patent 10,610,502 protect, and when does it expire?

Summary for Patent: 10,610,502